Immunsuppression beim nierentransplantierten Patienten über 65 Lebensjahre

Zusammenfassung

Ältere Patienten stellen eine zunehmende Population unter den Transplantierten. Leider sind die empirischen Daten zur immunsuppressiven Therapie in diesem Kollektiv bislang begrenzt. Die vorhandene Evidenz deutet jedoch darauf hin, dass verfügbare moderne Immunsuppressionsprotokolle unter Beachtung spezieller Besonderheiten bei älteren Patienten auch in dieser Klientel problemlos eingesetzt werden können. Dennoch sollten zukünftige randomisierte Studien ältere Empfänger einschließen, um die Empirik in dieser zunehmend größeren Population zu erweitern.

• Literatur

• 1 Pippias M, Jager KJ, Kramer A. et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant 2016; 31: 831-841 doi: 10.1093/ndt/gfv327
• 2 Rao PS, Merion RM, Ashby VB. et al. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation 2007; 83: 1069-1074 doi: 10.1097/01.tp.0000259621.56861.31
• 3 Perlman RL, Rao PS. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. Drugs Aging 2014; 31: 103-109 doi: 10.1007/s40266–013–0149-x
• 4 Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis?. Clin J Am Soc Nephrol 2006; 1: 532-538 doi: 10.2215/CJN.01130905
• 5 Ponticelli C, Podesta MA, Graziani G. Renal transplantation in elderly patients. How to select the candidates to the waiting list?. Transplant Rev (Orlando) 2014; 28: 188-192 doi: 10.1016/j.trre.2014.07.001
• 6 Watt KD, Pedersen RA, Kremers WK. et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010-2017 doi: 10.1053/j.gastro.2009.08.070
• 7 Fulop T, Larbi A, Witkowski JM. et al. Immunosenescence and cancer. Crit Rev Oncog 2013; 18: 489-513 doi: 10.1615/CritRevOncog.2013010597
• 8 Saule P, Trauet J, Dutriez V. et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev 2006; 127: 274-281 doi: 10.1016/j.mad.2005.11.001
• 9 Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des 2013; 19: 1680-1698 doi: 10.2174/​1381612811319090016
• 10 Frasca D, Diaz A, Romero M. et al. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011; 10: 330-335 doi: 10.1016/j.arr.2010.08.004
• 11 Shao M, Wan Q, Xie W. et al. Bloodstream infections among solid organ transplant recipients: epidemiology, microbiology, associated risk factors for morbility and mortality. Transplant Rev (Orlando) 2014; 28: 176-181 doi: 10.1016/j.trre.2014.02.001
• 12 Le Page AK, Mackie FE, McTaggart SJ. et al. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation. Nephrology (Carlton) 2013; 18: 813-819 doi: 10.1111/nep.12149
• 13 Ok Atilgan A, Ozdemir BH, Kirnap M. et al. Invasive fungal infections in liver transplant recipients. Exp Clin Transplant 2014; 12 (Suppl. 01) 110-116
• 14 Peev V, Reiser J, Alachkar N. Diabetes mellitus in the transplanted kidney. Front Endocrinol (Lausanne) 2014; 5: 141 doi: 10.3389/fendo.2014.00141
• 15 Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med 2011; 364: 1369-1370 ​doi: 10.1056/NEJMc1103007
• 16 Frei U, Noeldeke J, Machold-Fabrizii V. et al. Prospective age-matching in elderly kidney transplant recipients – ​a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008; 8: 50-57 doi: 10.1111/j.1600–6143.2007.02014.x
• 17 Jacobson PA, Schladt D, Oetting WS. et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 2012; 12: 3326-3336 doi; 10.1111/j.1600–6143.2012.04232.x
• 18 George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 727-730 doi: 10.1016/0006–2952(95)00192–3
• 19 Zahir H, McCaughan G, Gleeson M. et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57: 298-309 10.1046/j.1365–2125.2003.02008.x
• 20 Shah T, Kasravi A, Huang E. et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82: 1673-1676 doi: 10.1097/01.tp.0000250756.66348.9a
• 21 Pahlavani MA, Vargas DM. Influence of aging and caloric restriction on activation of Ras/MAPK, calcineurin, and CaMK-IV activities in rat T cells. Proc Soc Exp Biol Med 2000; 223: 163-169 doi: 10.1111/j.1525–1373.2000.22322.x
• 22 Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol 1996; 169: 185-195 doi: 10.1111/j.2040–1124.2010.00046.x
• 23 Kauffman HM, Cherikh WS, Cheng Y. et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889 doi: 10.1097/01.TP.0000184006.43152.8D
• 24 Zimmerman JJ, Lasseter KC, Lim HK. et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 2005; 45: 1368-1372 doi: 10.1177/0091270005281350
• 25 Kovarik JM, Sabia HD, Figueiredo J. et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001; 70: 425-430 doi: 10.1016/S0009–9236(01)15633-X
• 26 Tredger JM, Brown NW, Adams J. et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004; 10: 492-502 doi: 10.1002/lt.20124
• 27 Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther 1988; 43: 354-562 doi: 10.1038/clpt.1988.43
• 28 Tornatore KM, Logue G, Venuto RC. et al. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 1997; 37: 304-311 doi: 10.1002/j.1552–4604.1997.tb04307.x
• 29 Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab 1985; 60: 848-854 doi: 10.1210/jcem-60–5–848
• 30 Lebrun-Vignes B, Archer VC, Diquet B. et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-450 doi: 10.1046/j.1365–2125.2001.01372.x
• 31 Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32 (05) Pt 2 539-546 doi: 10.1016/S1262–3636(06)72809–9
• 32 Zhou Z, Shen J, Hong Y. et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther 2012; 92: 251-257 doi: 10.1038/clpt.2012.84
• 33 Agrawal A, Agrawal S, Cao JN. et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol 2007; 178: 6912-6922 doi: 10.4049/jimmunol.178.11.6912
• 34 Masson P, Henderson L, Chapman JR. et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014; CD010699 doi: 10.1002/14651858.CD010699.pub2
• 35 Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs macrophage polarization. J Interferon Cytokine Res 2012; 32: 18-26 doi: 10.1089/jir.2011.0058
• 36 Steinebrunner N, Sandig C, Sommerer C. et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes – a prospective study. Ann Transplant 2014; 19: 32-40 doi: 10.12659/AOT.889809
• 37 Leogrande D, Teutonico A, Ranieri E. et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 2007; 50: 314-325 doi: 10.1053/j.ajkd.2007.05.002
• 38 Gill J, Sampaio M, Gill JS. et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011; 6: 1168-1178 doi: 10.2215/CJN.07540810
• 39 Patel SJ, Knight RJ, Suki WN. et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant 2011; 25: E250-E256 doi: 10.1111/j.1399–0012.2010.01393.x
• 40 Woodle ES, First MR, Pirsch J. et al. Astellas Corticosteroid Withdrawal Study G. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577 doi: 10.1097/SLA.0b013e318187d1da
• 41 Badowski M, Gurk-Turner C, Cangro C. et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009; 23: 930-937 doi: 10.1111/j.1399–0012.2009.01028.x
• 42 Krenzien F, ElKhal A, Quante M. et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation 2015; 99: 2258-2268 doi: 10.1097/TP.0000000000000842
• 1 Keller F. Professor Doktor Hans-Eduard Franz 80 Jahre. Nieren Hochdruckkrh 2008; 37: 157